Form 4: CFO Buys 100,000 Shares of Cytosorbents
Statement of Changes in Beneficial Ownership
Cytosorbents Corp. Chief Financial Officer Peter J. Mariani acquired 100,000 shares of common stock through an open market purchase.
Summary
- Peter J. Mariani, Chief Financial Officer of Cytosorbents Corp., purchased 100,000 shares of common stock on June 15, 2026.
- The purchase was made through an open market transaction at a weighted average price of $0.44 per share, with individual transactions ranging from $0.40 to $0.45.
- Following this transaction, Mariani beneficially owns a total of 638,113 securities.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a positive signal due to significant insider buying by the CFO, indicating confidence in the company's value and future prospects.
Positives
- Insider buying activity, particularly by a CFO, can signal confidence in the company's future prospects.
- The purchase of 100,000 shares indicates a significant personal investment by a key executive.
Future Outlook
The filing does not contain specific forward-looking statements or guidance. However, the CFO's purchase of shares may imply a positive outlook from management.
Industry Context
StockSavvy.ai notes that insider purchases, especially by CFOs, are often viewed positively by the market as they can indicate a belief in the company's undervaluation or future growth potential within the medical device or biotechnology sector.
Stakeholder Impact
- Shareholders may view this purchase positively, interpreting it as a sign of management's confidence in the company's stock value.
Key Dates
| Date | Description |
|---|---|
| 06/15/2026 | Transaction Date for open market purchase of common stock. |
| 06/16/2026 | Date of signature on the Form 4 filing. |
| 08/14/2028 | Fourth anniversary from the date of grant for a portion of restricted stock units (RSUs). |
Recommendation
holdThe purchase by the CFO is a positive indicator, but without broader financial results or strategic updates in this specific filing, a 'hold' recommendation is prudent. Further analysis of the company's overall financial health and strategic direction is warranted before considering a stronger recommendation.
Keywords
Cytosorbents Corp, CTSO, Form 4, Insider Trading, Peter J. Mariani, Chief Financial Officer, Stock Purchase, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.